- |||||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Review, Journal: Covid-19 vaccines and variants of concern: A review. (Pubmed Central) - Jul 10, 2022
All nine had an efficacy over 50% against symptomatic Covid-19 disease: NVX-CoV2373 (∼96%), BNT162b2 (∼95%), mRNA-1273 (∼94%), Sputnik V (∼92%), AZD1222 (∼81%), BBIBP-CorV (∼79%), Covaxin (∼78%), Ad26.CoV.S (∼66%) and CoronaVac (∼51%)...Promising Covid-19 vaccines such as WIBP-CorV, AD5-nCOV, ZyCoV-D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. This review describes the most relevant mutations in the SARS-CoV-2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid-19 vaccination and introduces some promising Covid-19 vaccine candidates.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: The impact of COVID-19 vaccination program in the Republic of San Marino: focus on effectiveness of Gam-COVID-Vac. (Pubmed Central) - Jul 8, 2022
This review describes the most relevant mutations in the SARS-CoV-2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid-19 vaccination and introduces some promising Covid-19 vaccine candidates. Our study demonstrated the effectiveness of overall vaccination (Gam-COVID-Vac [84%] and BNT162b2 [16%]) in the prevention SARS-CoV-2 infection (pre-Omicron variant), waning over time but still with sustainable effectiveness against COVID-19-related hospitalization in the Republic of San Marino.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: COVID-19 vaccine demand protest might have increased vaccine acceptance and uptake in South Africa. (Pubmed Central) - Jul 8, 2022
The endorsement of COVID-19 vaccines by Malema, an influential political figure in South Africa, probably convinced some vaccine hesitant South Africans that COVID-19 vaccination is important. Therefore, we suggest vaccine endorsement by influential individuals in South Africa as one of the strategies to increase COVID-19 vaccine uptake.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Immunogenicity and Reactogenicity of the Booster Dose of COVID-19 Vaccines and Related Factors: A Panel Study from the General Population in Serbia. (Pubmed Central) - Jun 25, 2022
Sinopharm BBIBP-CorV (p < 0.001) and Sputnik V (p < 0.001), age 65 and over (p = 0.001) and currently smoking (p < 0.001) were independently associated with lower levels of anti-spike immunoglobulin G. Female sex (OR = 1.77; 95%CI = 1.01-3.12), previous COVID-19 infection (OR = 3.62; 95%CI = 1.13-11.63) and adverse events after the second dose (OR = 2.66; 95%CI = 1.33-5.32) were independently associated with intense systemic adverse events 7 days after. Booster dose significantly increased antibodies titers, especially 28 days after heterologous regimen, without a significant increase in reactogenicity.
- |||||||||| Tavalisse (fostamatinib) / Rigel, Kissei
Journal: Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/ R406 a potential candidate? (Pubmed Central) - Jun 22, 2022
On the other hand, several vaccines like Pfizer-BioNTech, Moderna, Johnson & Johnson's Janssen, Sputnik V, Covishield, Covaxin, etc., also evolved from the research study...Validation using subsequent docking study has also been performed on COVID-19 potential drugs with the available major COVID-19 crystal structures whose PDB IDs are: 6LU7, 6M2Q, 6W9C, 6M0J, 6M71 and 6VXX. Our computational study and docking results suggest that Fostamatinib (R406 as its active promoiety) may also be considered as one of the potential candidates for further clinical trials in pursuit to counter the spread of COVID-19.
- |||||||||| SARS-CoV2 vaccination in Hungarian IPF patients (TP-23 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_2709;
Majority (N=57) of patients also took a third dose: most patients received BNT162b2-mRNA-Pfizer/Biontech (58.82%), followed by BBIBP-CorV and mRNA-1273-Moderna (both 11.76 %)... SARS-CoV2 vaccination is utmost important in IPF patients, and independent of vaccine type used it resulted in significantly decreased risk of COVID-19 hospitalization.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Personalized predictions of adverse side effects to the COVID-19 vaccines (TP-21 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_1259;
This technique can serve as a tool to informed COVID-19 vaccine selection. An online interface at https://podsaf.org allows easy application of the model.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Study protocol: cohort event monitoring for safety signal detection after vaccination with COVID-19 vaccines in Iran. (Pubmed Central) - Jun 19, 2022
A live dashboard is also available for managers and policymakers. All data will be available on reasonable requests from the corresponding author.The use of the good and comprehensive guidelines provided by WHO, along with the accurate implementation of the protocol and continuous monitoring of the staff performance are the main strengths of this study which may be very useful for policymaking about COVID-19 vaccination.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Erythema Nodosum following a booster dose of Sputnik V SARS-CoV-2 vaccine: a case report (e-Poster Hall) - Jun 13, 2022 - Abstract #EADVSp2022EADV_Sp_177;
We hypothesised that a booster dose of Sputnik V could have triggered EN in our patient due to temporal and causal relation between vaccine administration and the onset of skin manifestations, since no other common cause could be found. Although EN in our case might be idiopathic, clinicians should be aware that COVID-19 vaccines could be a cause of EN.
- |||||||||| Journal, Adverse events: Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers. (Pubmed Central) - Jun 11, 2022
This study evaluated the self-reported post-vaccination side effects of inactivated (BBIBP-CorV and CoronaVac) and adenoviral vector-based (AZD1222, Gam-COVID-Vac and Ad26.COV2.S) vaccines among Algerian healthcare workers using a validated questionnaire...The risk factors associated with a higher prevalence of side effects included female gender, allergic individuals, individuals with regular medication, those who contracted the COVID-19 disease and those who received two doses for both inactivated and viral-based vaccines groups. Despite the higher prevalence of post-vaccination side effects among adenoviral vector vaccines recipients, both vaccines groups were equally effective in preventing symptomatic infections, and no life-threatening side effects were reported in either vaccine group.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain. (Pubmed Central) - Jun 8, 2022
We find no evidence of biased selection for any vaccine, but note waning protection of the Pfizer/BioNtech vaccine during the January to June 2021 period in the age > 60 y cohort; however, this cannot be distinguished from the overall fall in hospitalisations overall. Our findings support the value of vaccination in preventing COVID-19 related outcomes, provide real world estimates on the outcomes and frequencies of post-vaccination infections for the four vaccines, which may inform vaccine selection in the context of the Delta variant across the globe.
- |||||||||| Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
Enrollment closed: Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19) (clinicaltrials.gov) - Jun 3, 2022
P1/2, N=100, Active, not recruiting,
After the introduction of the GamCOVIDVac vaccine in adults, a decrease in the level of anti-Nc Abs was noted due to an increase in the proportion of RBD seropositive persons. Recruiting --> Active, not recruiting
- |||||||||| Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Trial completion: Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention (clinicaltrials.gov) - Jun 3, 2022
P2, N=100, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
Trial completion, Trial primary completion date: Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 (clinicaltrials.gov) - Jun 3, 2022
P1/2, N=100, Completed,
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2022 --> Nov 2021
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. (Pubmed Central) - May 30, 2022
We observed a 6.7- and 5-fold decrease in Sputnik V-vaccinated individuals experiencing asymptomatic or symptomatic infection, respectively. These results highlight the observation that the decrease in NtAb to the SARS-CoV-2 Omicron variant compared to the Wuhan variant occurs for different COVID-19 vaccines in use, with some showing no neutralization at all, confirming the necessity of a third booster vaccination.
- |||||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Retrospective data, Review, Journal: Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis. (Pubmed Central) - May 29, 2022
However, some questions regarding the safety of COVID-19 vaccines have been recently raised...Proportions of cases of stage III hypertension or hypertensive urgencies and emergencies was 0.6% (95% CI: 0.1% to 5.1%). In conclusion, abnormal BP is not rare after COVID-19 vaccination, but the basic mechanisms of this phenomenon are still unclear and require further research.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
SAFETY OF COVID-19 VACCINES IN PATIENTS WITH RHEUMATOID ARTHRITIS (PRELIMINARY DATA). () - May 24, 2022 - Abstract #EULAR2022EULAR_4026;
According to preliminary data, the tolerance of vaccines against COVID-19 in RA patients is satisfactory. Further studies are needed to study the safety, immunogenicity and clinical efficacy of immunization against COVID-19 in patients of this cohort.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Features of the humoral response to immunization "Gam-COVID-Vac" and in patients with COVID-19. (Pubmed Central) - May 24, 2022
Using a quantitative enzyme-linked immunosorbent assay, the levels of specific IgG were determined in persons who had had different degrees of severity before vaccination, in persons who were immuno-negative before immunization, as well as in convalescents who had undergone coronavirus infection of varying severity. The immunological targeting of antibodies against various SARS-CoV-2 proteins is considered.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Retrospective data, Journal, Adverse events: Adverse effects following COVID-19 vaccination in Iran. (Pubmed Central) - May 20, 2022
In this study, we demonstrate that the Sputnik V vaccine has the highest rate of adverse effects, followed by the AstraZeneca and Sinopharm vaccines. COVID-19 vaccines used in Iran are safe and there were no reports of serious adverse effects.
- |||||||||| OUTCOMES OF COVID-19 INFECTION IN PATIENTS WITH B AND PLASMA CELL MALIGNANCIES DURING THE THIRD WAVE IN ARGENTINA: A SINGLE CENTER EXPERIENCE () - May 13, 2022 - Abstract #EHA2022EHA_1570;
Nearly half of the pts had received a B-cell-depleting monoclonal antibody-based regimen: Rituximab (n=13), Daratumumab (n=4) or Obinutuzumab (n=1); the other half: other anti-myeloma therapy (n=5), chemotherapy (n=3), Ibrutinib (n=3), Venetoclax (n=2) or were untreated (n=7)...Twelve pts were treated with convalescent plasma, 9 received corticosteroids and 1 tocilizumab...Our findings show lower fatality rate than reported in previous waves, but still higher than the general vaccinated population. This might be explained because even if fully vaccinated, responsive patients fail to achieve protective levels of anti-spike antibodies.
- |||||||||| Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Uptake and barriers to COVID-19 vaccination in Thane, India: findings from a Community-Based Survey () - May 12, 2022 - Abstract #AIDS2022AIDS_1334;
Despite high interest in COVID-19 vaccination, over two-thirds of this community-based sample was not fully vaccinated. It is critical that vaccine programs integrate vaccine literacy and demand generation programs with mass vaccination programs to ensure optimal timely uptake.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
No effect of HBsAg positivity on antibody response after COVID-19 vaccine (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_2132;
P=N/A
This study showed no difference in SARS-CoV-2 IgG levels between control and HBsAg positive groups. SARS-CoV-2 IgG level was higher in participants with previous COVID-19 infection than those without COVID-19 infection.
|
